Adverse Drug Reactions (ADRs) are major global concern, adversely impacting patient safety and health outcomes. ADRs cause significant morbidity and mortality among hospitalised patients, causing greater length of hospital stay, increased healthcare costs and patient dissatisfaction to the treatments. Pharmacovigilance (PV), a process of detecting, monitoring and preventing drug-related harm, plays a vital role to ensure patient safety. ADR reporting is the cornerstone of PV. PV practices in Qatar are relatively new and are evolving rapidly. The purpose of this article is to explore the medication safety practices (notably ADR reporting) at the largest academic healthcare center in Qatar. The article further provides evidence on how information related to ADRs are generated and interpreted. Furthermore, it describes how a designated center for monitoring medication safety activities was established at the largest healthcare provider in Qatar.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
World Health Organization. Reporting and learning systems for medication errors: the role of pharmacovigilance centers. 2014. http://apps.who.int/medicinedocs/documents/s21625en/s21625en.pdf. Accessed 05 Feb 2018.
World Health Organization. International drug monitoring: the role of the hospital, report of a WHO meeting [held in Geneva from 18 to 23 November 1968]. 1969. http://apps.who.int/iris/bitstream/10665/40747/1/WHO_TRS_425.pdf. Accessed 05 Feb 2018.
Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294(10):1255–9.
Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol. 2008;65(4):573–9.
Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009;4(2):e4439.
Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with adverse drug reactions following hospital admission. Drug Saf. 2008;31(9):789–98.
Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol. 2008;65(3):396–406.
Khan LM, Al-Harthi S, Saadah OI. Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharm J. 2013;21(3):261–6.
Sridhar SB, Al-Thamer SSF, Jabbar R. Monitoring of adverse drug reactions in psychiatry outpatient department of a Secondary Care Hospital of Ras Al Khaimah, UAE. J Basic Clin Pharm. 2016;7(3):80.
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–5.
Ministry of Development Planning and Statistics. Total population within the State of Qatar. 2017. http://www.mdps.gov.qa/portal/page/portal/gsdp_en/statistics_en/monthly_preliminary_figures_on_population_en. Accessed 10 Jan 2018.
Ministry of Public Health (MoPH) Qatar. Health objectives: ministry of public health. 2017. https://phs.moph.gov.qa/current-status/. Accessed 10 Jan 2018.
Ministry of Public Health, Qatar. Health services. 2018. https://www.moph.gov.qa/health-services/Pages/default.aspx. Accessed 22 Jan 2018.
National Health Strategy 2011–2016. Healthcare products regulation. General secretariat, supreme council of health. 2014. www.nhsq.info/strategy-goals-and./national-health/healthcare-products-regulation. Accessed 10 Jan 2018.
Joint Commission International (JCI). JCI-accredited organizations. 2017. https://www.jointcommissioninternational.org/about-jci/jci-accredited-organizations/?c=Qatar. Accessed 19 Dec 2017.
The Institute for Healthcare Improvement. Current collaborations in the region—Qatar-Hamad Medical Corporation. Institute for healthcare improvement. 2018. http://www.ihi.org/regions/MiddleEast/Pages/OurWork.aspx. Accessed 10 Jan 2018.
International Medication Safety Network (IMSN). Medication safety and quality center (MSQC): Qatar. 2018. https://www.intmedsafe.net/about/imsn-members/. Accessed 10 Jan 2018.
WHO Program for International Drug Monitoring. Associate members: Qatar. 2018. https://www.who-umc.org/global-pharmacovigilance/members/who-programme-members/. Accessed 10 Jan 2018.
Steurbaut S, Hanssens Y. Pharmacovigilance: empowering healthcare professionals and patients. Int J Clin Pharm. 2014;36(5):859–62.
ElKassem W, Al Hail M, Rouf A, Hamad A, Thomas B. An evaluation of knowledge, attitude and practice of pharmacists towards adverse drug reactions: a questionnaire based study at Hamad Medical Corporation, Qatar. 2017. https://www.eventscribe.com/2017/ASHPMeeting/ajaxcalls/PosterInfo.asp?efp=WUFORk1KUU8yMDk5&PosterID=117702&rnd=0.5433606. Accessed 10 Jan 2018.
Almandil NB. Healthcare professionals’ awareness and knowledge of adverse drug reactions and pharmacovigilance. Saudi Med J. 2016;37(12):1359–64.
Alshammari TM, Alamri KK, Ghawa YA, Alohali NF, Abualkol SA, Aljadhey HS. Knowledge and attitude of health-care professionals in hospitals towards pharmacovigilance in Saudi Arabia. Int J Clin Pharm. 2015;37(6):1104–10.
Hajebi G, Mortazavi SA, Salamzadeh J, Zian A. A survey of knowledge, attitude and practice of nurses towards pharmacovigilance in Taleqani Hospital. Iran J Pharm Res (IJPR). 2010;9(2):199–206.
No funding was received for this paper.
Conflicts of interest
All the authors declare that they have no conflict of interest.
About this article
Cite this article
Al Hail, M., Elkassem, W., Hamad, A. et al. Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar. Int J Clin Pharm 40, 769–774 (2018). https://doi.org/10.1007/s11096-018-0629-5
- Adverse Drug Reactions
- Hamad Medical Corporation
- Medication safety